Kamada

Kamada

Biotechnology
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

$446.7M

Market Cap • 11/20/2026

1990

(36 years)

Founded

2013

(13 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Israel

Israel

Country

Valuation

P/B

1,7

P/S

2,3

P/EBITDA

9,7

P/OCF

9,9

P/FCF

12,5

P/E

18

BVPS

4,7

EPS

0,4

Market Cap

Market Cap

446,7M

EV

383,1M

EV/Revenue

1,9

EV/EBITDA

8,4

EV/EBIT

12,6

Payout

Dividend Per Share

0,4

Dividend Yield

5,4%

Buyback Yield

0%

Total Yield

5,4%

Dividend Yield 5Y

2,3%

Payout

97,1%

Retained Earnings

-19,9M

Profitability

Gross Margin

41,6%

EBITDA Margin

23,3%

EBIT Margin

15,4%

Net Margin

12,7%

D&A/EBITDA

0%

R&D/Revenue

4,9%

Capex/Revenue

4,8%

Capex/D&A

60,9%

Capex/OCF

20,8%

SBC/OCF

6,4%

% PPE

13,8%

% Goodwill

7,9%

ROE

9,4%

ROIC

9,7%

Growth

CAGR Revenue 5Y

13,7%

CAGR Op. Income 5Y

42%

CAGR Net Income 5Y

38,1%

CAGR EPS 5Y

19%

CAGR OCF 5Y

38,4%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

4,2

Quick Ratio

2,2

Interest Coverage

2877,4%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium